These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33560717)

  • 41. The role of Ga
    Erdogan M; Sengul SS; Cetin B; Avcı M; Yagci S; Ozkoç I; Barikan DE; Yildiz M
    Ann Nucl Med; 2022 Jun; 36(6):562-569. PubMed ID: 35397091
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of
    Can C; Gündoğan C; Yildirim OA; Poyraz K; Güzel Y; Kömek H
    Hell J Nucl Med; 2021; 24(1):25-35. PubMed ID: 33866336
    [TBL] [Abstract][Full Text] [Related]  

  • 43.
    Esen T; Falay O; Tarim K; Armutlu A; Koseoglu E; Kilic M; Seymen H; Sarikaya AF; Kiremit MC; Balbay MD; Canda AE; Baydar DE; Kordan Y; Demirkol MO; Tilki D
    Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
    Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
    Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study.
    Ucar T; Gunduz N; Demirci E; Culpan M; Gunel H; Kir G; Atis RG; Yildirim A
    Prostate; 2022 Nov; 82(15):1462-1468. PubMed ID: 35915579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
    Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
    Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Should 68Ga-PSMA PET/CT Replace CT and Bone Scan in Clinical Staging of High-risk Prostate Cancer?
    Pepe P; Pennisi M
    Anticancer Res; 2022 Mar; 42(3):1495-1498. PubMed ID: 35220244
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection.
    Dekalo S; Kuten J; Mintz I; Fahoum I; Gitstein G; Keizman D; Sarid D; Matzkin H; Mabjeesh NJ; Beri A; Even-Sapir E; Yossepowitch O; Mano R
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):910-916. PubMed ID: 33790418
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
    BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    Liu C; Liu T; Zhang N; Liu Y; Li N; Du P; Yang Y; Liu M; Gong K; Yang X; Zhu H; Yan K; Yang Z
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1852-1861. PubMed ID: 29717333
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Total-Body
    Pomykala KL; Czernin J; Grogan TR; Armstrong WR; Williams J; Calais J
    J Nucl Med; 2020 Mar; 61(3):405-411. PubMed ID: 31541035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlation between Prostate Cancer Positive Cores and 68Ga-PSMA Distribution in Prostate Gland.
    Çankaya S; Caylan AE; Aydin F; Uçar M; Kutlu Ö
    Urol Int; 2024; 108(1):65-72. PubMed ID: 38016433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Confirmation of PSMA expression measured on [68Ga]Ga-PSMA PET/CT by immunohistochemistry in prostate adenocarcinoma.
    Sengoz T; Sen Turk N; Ozlulerden Y; Celen S; Gultekin A; Yaylali O; Yuksel D
    Nucl Med Rev Cent East Eur; 2023; 26(0):68-73. PubMed ID: 37381796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
    Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PSMA whole-body tumor burden in primary staging and biochemical recurrence of prostate cancer.
    Santos A; Mattiolli A; Carvalheira JB; Ferreira U; Camacho M; Silva C; Costa F; Matheus W; Lima M; Etchebehere E
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):493-500. PubMed ID: 32789680
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer.
    Kopp D; Kopp J; Bernhardt E; Manka L; Beck A; Gerullis H; Karakiewicz PI; Salomon G; Wiggermann P; Hammerer P; Schiffmann J
    Urol Int; 2022; 106(1):56-62. PubMed ID: 33965965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gallium-68-prostate-specific membrane antigen (
    van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
    Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The clinical consequences of routine
    Zacho HD; Nalliah S; Petersen A; Petersen LJ
    Scand J Urol; 2022; 56(5-6):353-358. PubMed ID: 36073096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.